Illinois Municipal Retirement Fund decreased its position in shares of Elevance Health, Inc. (NYSE:ELV – Free Report) by 2.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 62,010 shares of the company’s stock after selling 1,810 shares during the period. Illinois Municipal Retirement Fund’s holdings in Elevance Health were worth $18,153,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in shares of Elevance Health during the 4th quarter valued at $1,058,165,000. Wellington Management Group LLP grew its stake in Elevance Health by 25.2% during the 4th quarter. Wellington Management Group LLP now owns 8,289,976 shares of the company’s stock worth $2,906,051,000 after buying an additional 1,668,679 shares during the last quarter. Price T Rowe Associates Inc. MD grew its stake in Elevance Health by 27.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,446,185 shares of the company’s stock worth $2,610,261,000 after buying an additional 1,607,274 shares during the last quarter. Invesco Ltd. increased its position in Elevance Health by 50.3% during the 4th quarter. Invesco Ltd. now owns 3,903,878 shares of the company’s stock valued at $1,368,505,000 after buying an additional 1,306,390 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its position in Elevance Health by 79.3% during the 4th quarter. Bank of New York Mellon Corp now owns 2,408,704 shares of the company’s stock valued at $844,371,000 after buying an additional 1,065,065 shares in the last quarter. 89.24% of the stock is currently owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several brokerages have weighed in on ELV. Guggenheim raised their price target on Elevance Health from $396.00 to $399.00 and gave the stock a “buy” rating in a report on Friday, April 24th. Wells Fargo & Company upped their price objective on shares of Elevance Health from $391.00 to $492.00 and gave the company an “overweight” rating in a report on Monday. Robert W. Baird increased their price objective on shares of Elevance Health from $317.00 to $331.00 and gave the company a “neutral” rating in a research report on Thursday, April 23rd. Sanford C. Bernstein lifted their target price on shares of Elevance Health from $424.00 to $482.00 and gave the stock an “outperform” rating in a research note on Thursday, July 2nd. Finally, Deutsche Bank Aktiengesellschaft raised shares of Elevance Health from a “hold” rating to a “buy” rating and boosted their target price for the stock from $363.00 to $498.00 in a research report on Wednesday, May 20th. Fifteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat, Elevance Health currently has an average rating of “Moderate Buy” and a consensus target price of $435.05.
Insiders Place Their Bets
In other Elevance Health news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the completion of the transaction, the director directly owned 10,734 shares of the company’s stock, valued at approximately $4,312,599.18. This trade represents a 1.39% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.34% of the company’s stock.
Elevance Health News Summary
Here are the key news stories impacting Elevance Health this week:
- Positive Sentiment: Elevance Health beat Q2 estimates, reporting EPS of $7.45 versus $6.18 expected and revenue of $49.83 billion versus $48.84 billion projected. Elevance Health Reports Second Quarter 2026 Results; Raises Full-Year Guidance
- Positive Sentiment: The company raised its 2026 adjusted EPS guidance to at least $27.00, suggesting management expects improved operating performance and better medical cost control ahead. Elevance raises annual profit forecast on better medical cost management
- Positive Sentiment: Management said results were supported by disciplined execution, improved operating performance, and lower medical costs in some plans, which could help margins recover. Elevance Health Profits Eclipse $1.4 Billion As Costs Ease Somewhat
- Neutral Sentiment: Elevance also announced a quarterly dividend of $1.72 per share, reinforcing its shareholder-return profile. MarketBeat dividend notice
- Negative Sentiment: Despite the beat, the stock is being pressured by margin concerns, including a higher benefit-expense ratio and ongoing cost pressure in parts of the business. Elevance Health Raises Earnings Outlook on Higher Sales
- Negative Sentiment: Year-over-year EPS fell from $8.84, and softer membership plus higher expenses suggest earnings momentum is not yet fully stable. ELV Beats Q2 Earnings Estimates on Higher CarelonRx Product Revenues
Elevance Health Stock Performance
Shares of ELV opened at $389.85 on Thursday. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a 50-day moving average of $399.67 and a two-hundred day moving average of $355.07. The stock has a market cap of $84.66 billion, a P/E ratio of 16.58, a P/E/G ratio of 2.42 and a beta of 0.67. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $436.24.
Elevance Health (NYSE:ELV – Get Free Report) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $7.45 earnings per share for the quarter, beating analysts’ consensus estimates of $6.21 by $1.24. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The business had revenue of $49.83 billion for the quarter, compared to analyst estimates of $48.88 billion. During the same period in the prior year, the company earned $8.84 earnings per share. The company’s revenue was up .8% on a year-over-year basis. As a group, research analysts predict that Elevance Health, Inc. will post 26.86 EPS for the current year.
Elevance Health Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, September 25th. Investors of record on Thursday, September 10th will be given a $1.72 dividend. The ex-dividend date is Thursday, September 10th. This represents a $6.88 dividend on an annualized basis and a yield of 1.8%. Elevance Health’s dividend payout ratio is currently 29.26%.
About Elevance Health
Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.
Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.
Read More
- Five stocks we like better than Elevance Health
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Want to see what other hedge funds are holding ELV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elevance Health, Inc. (NYSE:ELV – Free Report).
Receive News & Ratings for Elevance Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevance Health and related companies with MarketBeat.com's FREE daily email newsletter.
